Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

NameBrand nameTypeSourceTargetApprovedUse
3F8mabmouseGD2 gangliosideneuroblastoma
Abagovomab[1]mabmouseCA-125 (imitation)ovarian cancer
Abciximab[2]ReoProFabchimericCD41 (integrin alpha-IIb)Y[3]platelet aggregation inhibitor
Abituzumab[4]mabhumanizedCD51cancer
Abrezekimab[5]FabhumanizedIL-13
Abrilumab[6]mabhumanintegrin α4 β7inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab[6]mabhumanClostridium difficileClostridium difficile colitis
Adalimumab[7]HumiramabhumanTNF-αY[8]rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hemolytic disease of the newborn
Adecatumumab[9]mabhumanEpCAMprostate and breast cancer
Aducanumab[10]AduhelmmabhumanAmyloid betaY[11]Alzheimer's disease
Afasevikumab[12]mabhumanIL-17A, IL-17Fmultiple sclerosis
Afelimomab[2]F(ab')2mouseTNF-αsepsis
Alacizumab pegol[13]F(ab')2humanizedVEGFR2cancer
Alemtuzumab[14]Lemtrada, CampathmabhumanizedCD52Ymultiple sclerosis
Alirocumab[15]PraluentmabhumanPCSK9Yhypercholesterolemia
Altumomab pentetateHybri-ceakermabmouseCarcinoembryonic antigen (CEA)colorectal cancer (diagnosis)
Amatuximab[16]mabchimericmesothelincancer
AmivantamabRybrevantBsAbhumanEpidermal growth factor receptor (EGFR), cMetYnon-small cell lung cancer
Anatumomab mafenatox[17]FabmouseTumor-associated glycoprotein 72 (TAG-72)non-small cell lung cancer
Andecaliximab[18]mabchimericgelatinase Bgastric cancer or gastroesophageal junction adenocarcinoma
Anetumab ravtansine[4]mabhumanmesothelin (MSLN)cancer
Anifrolumab[4]SaphnelomabhumanIFN-α/β receptorY[19]systemic lupus erythematosus
AnsuvimabEbangamabhumanEbola virus glycoproteinYtreatment of Zaire ebolavirus (Ebola virus)
Anrukinzumab[13]
(= IMA-638)[20]
mabhumanizedIL-13asthma
Apolizumab[21]mabhumanizedHLA-DRhematological cancers
Aprutumab ixadotin[22]mabhumanFGFR2
Arcitumomab[23]CEA-ScanFab'mouseCarcinoembryonic antigen (CEA)gastrointestinal cancers (diagnosis)
Ascrinvacumab[12]mabhumanactivin receptor-like kinase 1cancer
Aselizumab[24]mabhumanizedL-selectin (CD62L)severely injured patients
Atezolizumab[25]TecentriqmabhumanizedPD-L1Ycancer
Atidortoxumab[26]mabhumanStaphylococcus aureus alpha toxin
Atinumab[16]mabhumanRTN4
Atoltivimabmabhumanpart of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Atoltivimab/maftivimab/odesivimabInmazebmabhumanYtreatment of Zaire ebolavirus (Ebola virus)
Atorolimumab[2]mabhumanRhesus factorhemolytic disease of the newborn
Avelumab[12]BavenciomabhumanPD-L1Ycancer
Azintuxizumab vedotin[27]mabchimeric/
humanized
CD319cancer
Bamlanivimab[28]mabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Emergency Use Authorization (EUA) when used with etesevimab[29]COVID-19
Bapineuzumab[30]mabhumanizedβ-amyloidAlzheimer's disease
Basiliximab[31]SimulectmabchimericCD25 (α chain of IL-2 receptor)Yprevention of organ transplant rejections
Bavituximab[1]mabchimericphosphatidylserinecancer, viral infections
BCD-100humanPD-1melanoma
Bebtelovimab[32]mabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Emergency Use Authorization (EUA)[33]COVID-19
Bectumomab[31]LymphoScanFab'mouseCD22non-Hodgkin's lymphoma (detection)
Bedinvetmab[34]Librela[35]mabveterinarynerve growth factor (NGF)[35]Ypain associated with osteoarthritis in dogs[35]
Begelomab[6]mabmouseDPP4
Belantamab mafodotin[5]BlenrepmabhumanizedB-cell maturation antigen (BCMA)Yrelapsed or refractory multiple myeloma
Belimumab[36]BenlystamabhumanB-cell activating factor (BAFF)Ysystemic lupus erythematosus without renal or CNS involvement
Bemarituzumab[26]mabhumanizedFGFR2gastric cancer or gastroesophageal junction adenocarcinoma
Benralizumab[37]FasenramabhumanizedCD125Yasthma
Berlimatoxumab[26]mabhumanStaphylococcus aureus bi-component leukocidin
Bermekimab[31]XilonixmabhumanIL-1αcolorectal cancer
Bersanlimab[5]mabhumanICAM-1
Bertilimumab[24]mabhumanCCL11 (eotaxin-1)severe allergic disorders
Besilesomab[38]ScintimunmabmouseCarcinoembryonic antigen (CEA)-related antigeninflammatory lesions and metastases (detection)
Bevacizumab[14]AvastinmabhumanizedVEGF-AYmetastatic cancer, retinopathy of prematurity
Bezlotoxumab[31]ZinplavamabhumanClostridium difficileYClostridium difficile colitis
Biciromab[31]FibriScintFab'mousefibrin II, beta chainthromboembolism (diagnosis)
Bimagrumab[39]mabhumanACVR2Bmyostatin inhibitor
Bimekizumab[10]BimzelxmabhumanizedIL-17A, IL-17F, IL-17AFYpsoriasis
Birtamimabmabchimericserum amyloid A proteinamyloidosis
Bivatuzumab[31]mabhumanizedCD44 v6squamous cell carcinoma
Bleselumab[12]mabhumanCD40organ transplant rejection
Blinatumomab[31]BlincytoBiTEmouseCD19Ypre-B Acute lymphoblastic leukemia (ALL) (CD19+)
Blontuvetmab[40]BlontressmabveterinaryCD20
Blosozumab[41]mabhumanizedSOSTosteoporosis
Bococizumab[31]mabhumanizedPCSK9dyslipidemia
Brazikumab[18]mabhumanIL-23Crohn's disease
Brentuximab vedotin[31]AdcentrismabchimericCD30 (TNFRSF8)YHodgkin's lymphoma, anaplastic large-cell lymphoma
Briakinumab[31]mabhumanIL-12, IL-23psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab[41]SiliqmabhumanIL-17YPlaque psoriasis
Brolucizumab[25]BeovuscFvhumanizedvascular endothelial growth factor A (VEGFA)Ywet age-related macular degeneration
Brontictuzumab[6]mabhumanizedNotch 1cancer
Burosumab[18]CrysvitamabhumanFGF 23YX-linked hypophosphatemia
Cabiralizumab[40]mabhumanizedCSF1Rmetastatic pancreatic cancer
Camidanlumab tesirine[26]mabhumanCD25 (α chain of IL-2 receptor)B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia
Camrelizumab[22]mabhumanizedPD-1hepatocellular carcinoma
Canakinumab[42]IlarismabhumanIL-1Ycryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease
Cantuzumab mertansine[41]mabhumanizedCanAg (a glycoform of MUC1)colorectal cancer etc.
Cantuzumab ravtansine[41]mabhumanizedCanAg (a glycoform of MUC1)cancers
Caplacizumab[43]CablivisdAbhumanizedVWFYthrombotic thrombocytopenic purpura, thrombosis
Casirivimab[28]mabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Yes when used with imdevimab[44][45]COVID-19
Capromab[31]ProstascintmabmouseGlutamate carboxypeptidase IIYprostate cancer (detection)
Carlumab[16]mabhumanMCP-1oncology/immune indications
Carotuximab[40]mabchimericendoglinangiosarcoma
Catumaxomab[30]Removab3functrat/mouse hybridEpCAM, CD3Yovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugatemabhumanizedLewis-Y antigencancer
Cedelizumab[46]mabhumanizedCD4prevention of organ transplant rejections, treatment of autoimmune diseases
Cemiplimab[31]LibtayomabhumanPD-1Ycutaneous squamous cell carcinoma
Cergutuzumab amunaleukin[12]mabhumanizedIL-2cancer
Certolizumab pegol[42]CimziaFab'humanizedTNF-αYCrohn's disease, rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis
Cetrelimab[5]mabhumanPD-1cancer
Cetuximab[31]ErbituxmabchimericEpidermal growth factor receptor (EGFR)Ymetastatic colorectal cancer and head and neck cancer
Cibisatamab[5]mabhumanizedCEACAM5cancer
Cilgavimab[28]mabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Emergency Use Authorization (EUA) when used with tixagevimab[47]COVID-19
Cirmtuzumab[31]humanizedROR1chronic lymphocytic leukemia
Citatuzumab bogatox[48]FabhumanizedEpCAMovarian cancer and other solid tumors
Cixutumumab[31]mabhumanIGF-1 receptor (CD221)solid tumors
Clazakizumab[49]mabhumanizedIL-6rheumatoid arthritis
Clenoliximab[31]mabchimericCD4rheumatoid arthritis
Clivatuzumab tetraxetan[31]hPAM4-CidemabhumanizedMUC1pancreatic cancer
Codrituzumab[4]mabhumanizedglypican 3cancer
Cofetuzumab pelidotin[26]mabhumanizedPTK7cancer
Coltuximab ravtansine[4]mabchimericCD19cancer
Conatumumab[48]mabhumanTRAIL-R2cancer
Concizumab[50]Alhemomabhumanizedtissue factor pathway inhibitor (TFPI)Ybleeding with hemophilia
Cosfroviximab[27]ZMappmabchimericebolavirus glycoproteinEbola virus
Crenezumab[31]mabhumanizedβ-amyloid (1-40 and 1-42)Alzheimer's disease
Crizanlizumab[22]Adakveomabhumanizedselectin PYsickle-cell disease
Crotedumab[40]mabhumanglucagon receptor (GCGR)diabetes
CR6261mabhumanHemagglutinin (influenza)infectious disease/influenza A
Cusatuzumab[5]mabhumanizedCD70cancer
Dacetuzumab[13]mabhumanizedCD40hematologic cancers
Daclizumab[51]ZenapaxmabhumanizedCD25 (α chain of IL-2 receptor)Yprevention of organ transplant rejections, multiple sclerosis
DalotuzumabmabhumanizedIGF-1 receptor (CD221)cancer etc.
Dapirolizumab pegol[52]mabhumanizedCD154 (CD40L)
Daratumumab[53]DarzalexmabhumanCD38Y[54]multiple myeloma
Dectrekumab[25]mabhumanIL-13
DemcizumabmabhumanizedDLL4cancer
Denintuzumab mafodotin[6]mabhumanizedCD19cancer
Denosumab[55]ProliamabhumanRANKLYosteoporosis, bone metastases etc.
Depatuxizumab mafodotin[22]mabchimeric/
humanized
EGFRglioblastoma
Derlotuximab biotinmabchimerichistone complexrecurrent glioblastoma multiforme
DetumomabmabmouseB-lymphoma celllymphoma
Dezamizumab[22]mabhumanizedserum amyloid P component
DinutuximabUnituxinmabchimericGD2 gangliosideYneuroblastoma
Dinutuximab betaQarzibamabchimericGD2 gangliosideYneuroblastoma
DiridavumabmabhumanHemagglutinin (influenza)influenza A
Domagrozumab[40]mabhumanizedGDF-8Duchenne muscular dystrophy
Donanemab mab humanized Amyloid beta Alzheimer's disease
Dorlimomab aritox[56]F(ab')2mouse
Dostarlimab[57]JemperlimabhumanizedPCDP1Yendometrial cancer
DrozitumabmabhumanDR5cancer etc.
DS-8201humanizedHER2gastric or gastroesophageal junction adenocarcinoma
Duligotuzumab[15]mabhumanizedERBB3 (HER3)testicular cancer
Dupilumab[39]DupixentmabhumanIL-4RαYatopic dermatitis, asthma, nasal polyps
Durvalumab[25]ImfinzimabhumanPD-L1Ycancer
DusigitumabmabhumanIGF-2B-cell malignancies
Duvortuxizumab[27]scFvchimeric/
humanized
CD19, CD3Ecancer
Ecromeximab[21]mabchimericGD3 gangliosidemalignant melanoma
Eculizumab[21]SolirismabhumanizedC5Yparoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Edobacomabmabmouseendotoxinsepsis caused by Gram-negative bacteria
EdrecolomabPanorexmabmouseEpCAMcolorectal carcinoma
Efalizumab[7]RaptivamabhumanizedLFA-1 (CD11a)psoriasis (blocks T-cell migration)
Efungumab[1]MycograbscFvhumanHsp90invasive Candida infection
Eldelumab[4]mabhumanCXCL10 (IP-10)Crohn's disease, ulcerative colitis
Elezanumab[22]mabhumanrepulsive guidance molecule A (RGMA)spinal cord injury and multiple sclerosis
Elgemtumab[25]mabhumanERBB3 (HER3)cancer
ElotuzumabEmplicitimabhumanizedSLAMF7Ymultiple myeloma
ElsilimomabmabmouseIL-6
Emactuzumab[6]mabhumanizedCSF1Rcancer
Emapalumab[22]GamifantmabhumanIFN-γYhemophagocytic lymphohistiocytosis
EmibetuzumabmabhumanizedHGFRcancer
Emicizumab[12]HemlibraBsAbhumanizedactivated F9, F10Yhaemophilia A
Enapotamab vedotin[5]mabhumanAXLcancer
EnavatuzumabmabhumanizedTWEAK receptorcancer etc.
Enfortumab vedotin[4]Padcevmabhumannectin-4Y[58]urothelial cancer
Enlimomab pegol[59]mabmouseICAM-1 (CD54)
Enoblituzumab[22]mabhumanizedCD276cancer
EnokizumabmabhumanizedIL-9asthma
Enoticumab[15]mabhumanDLL4
EnsituximabmabchimericMUC5ACcancer
EpcoritamabEpkinly[60][61]BiTEhumanizedCD3, CD20Ydiffuse large B-cell lymphoma
Epitumomab cituxetan[62]mabmouseepisialin
EpratuzumabmabhumanizedCD22cancer, systemic lupus erythematosus (SLE)
Eptinezumab[22]Vyeptimabhumanizedcalcitonin gene-related peptideY[63]migraine
Erenumab[22]Aimovigmabhumancalcitonin gene-related peptide receptor (CGRP)Ymigraine
Erlizumab[64]F(ab')2humanizedITGB2 (CD18)heart attack, stroke, traumatic shock
Ertumaxomab[30]Rexomun3functrat/mouse hybridHER2/neu, CD3Ybreast cancer etc.
EtaracizumabAbegrinmabhumanizedintegrin αvβ3Ymelanoma, prostate cancer, ovarian cancer etc.
Etesevimab[28]mabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Emergency Use Authorization (EUA) when used with bamlanivimab[29]COVID-19
Etigilimab[5]mabhumanizedTIGIT
Etrolizumab[16]mabhumanizedintegrin β7inflammatory bowel disease
EvinacumabEvkeezamabhumanangiopoietin 3Ydyslipidemia
Evolocumab[39]RepathamabhumanPCSK9Yhypercholesterolemia
Exbivirumab[65]mabhumanhepatitis B surface antigenhepatitis B
Fanolesomab[17]NeutroSpecmabmouseCD15appendicitis (diagnosis)
FaralimomabmabmouseIFN receptor
Faricimab[66]VabysmomabhumanizedVEGF-A and Ang-2Yangiogenesis, ocular vascular diseases
Farletuzumabmabhumanizedfolate receptor 1ovarian cancer
Fasinumabmabhumannerve growth factor (NGF)acute sciatic pain
FBTA05[67][68]Lymphomun3functrat/mouse hybridCD20chronic lymphocytic leukaemia
Felvizumabmabhumanizedrespiratory syncytial virusrespiratory syncytial virus infection
Fezakinumab[69][70]mabhumanIL-22rheumatoid arthritis, psoriasis
Fibatuzumab[71]mabhumanizedephrin receptor A3
FiclatuzumabmabhumanizedHepatocyte growth factor (HGF)cancer etc.
FigitumumabmabhumanIGF-1 receptor (CD221)adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab[6]mabhumanHemagglutinin (influenza)
FlanvotumabmabhumanTYRP1 (glycoprotein 75)melanoma
FletikumabmabhumanIL-20rheumatoid arthritis
Flotetuzumab[5]di-scFvhumanizedIL-3 receptorhematological malignancies
Fontolizumab[21]HuZAFmabhumanizedIFN-γCrohn's disease etc.
Foralumab[72]mabhumanCD3E
Foravirumab[48]mabhumanrabies virus glycoproteinrabies (prophylaxis)
Fremanezumab[22]Ajovymabhumanizedcalcitonin gene-related peptide alpha and betaYmigraine
Fresolimumab[53]mabhumanTGF-βidiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Frovocimab[57]mabhumanizedPCSK9hypercholesterolemia
Frunevetmab[73]Solensia[74]mabveterinarynerve growth factor (NGF)[74]Ypain associated with osteoarthritis in cats[74]
Fulranumabmabhumannerve growth factor (NGF)pain
Futuximab[15]mabchimericEpidermal growth factor receptor (EGFR)cancer
Galcanezumab[40]EmgalitymabhumanizedcalcitoninYmigraine
GaliximabmabchimericCD80B-cell lymphoma
GancotamabscFvhumanHER2/neucancer
GanitumabmabhumanIGF-1 receptor (CD221)cancer
Gantenerumab[42]mabhumanβ-amyloid (1-40 and 1-42)Alzheimer's disease
Gatipotuzumab[27]mabhumanizedMUC1cancer
Gavilimomab[64]mabmouseCD147 (basigin)graft versus host disease
Gedivumab[27]mabhumanHemagglutinin (influenza)
Gemtuzumab ozogamicin[22]MylotargmabhumanizedCD33Yacute myelogenous leukemia
GevokizumabmabhumanizedIL-1βdiabetes etc.
Gilvetmab[27]mabveterinaryPCDC1
Gimsilumab[26]mabhumanCSF2rheumatoid arthritis
Girentuximab[53]Rencarexmabchimericcarbonic anhydrase 9 (CA-IX)clear cell renal cell carcinoma[75]
Glembatumumab vedotin[37][76]mabhumanGPNMBmelanoma, breast cancer
Glofitamab[60]Columvi[77]BsAbhumanizedCD20, CD3Y[77]diffuse large B-cell lymphoma[77]
Golimumab[65]SimponimabhumanTNF-αYrheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
GomiliximabmabchimericCD23 (IgE receptor)allergic asthma
Gosuranemabmabhumanizedtau proteinprogressive supranuclear palsy
GuselkumabTremfyamabhumanIL-23Ypsoriasis
Ianalumab[26]mabhumanBAFF-Rautoimmune hepatitis
Ibalizumab[42]TrogarzomabhumanizedCD4YHIV infection
SintilimabhumanPD-1squamous cell non-small cell lung cancer
Ibritumomab tiuxetanZevalinmabmouseCD20Ynon-Hodgkin's lymphoma
IcrucumabmabhumanVEGFR-1cancer etc.
Idarucizumab[4]PraxbindmabhumanizeddabigatranYreversal of anticoagulant effects of dabigatran
Ifabotuzumab[22]mabhumanizedEPHA3glioblastoma multiforme[78]
IgovomabIndimacis-125F(ab')2mouseCA-125ovarian cancer (diagnosis)
Iladatuzumab vedotin[26]mabhumanizedCD79Bcancer
Imalumab[6]mabhumanmacrophage migration inhibitory factor (MIF)cancer
Imaprelimab[5]mabhumanizedmelanoma cell adhesion molecule (MCAM)
ImciromabMyoscintmabmousecardiac myosinYcardiac imaging
Imdevimab[28]mabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Yes when used with casirivimab[44][45]COVID-19
Imgatuzumab[15]mabhumanizedEpidermal growth factor receptor (EGFR)cancer
Inclacumab[43]mabhumanselectin Pcardiovascular disease
Indatuximab ravtansine[41]mabchimericSDC1cancer
Indusatumab vedotin[25]mabhumanGUCY2Ccancer
Inebilizumab[12]UpliznamabhumanizedCD19Y[79]cancer, systemic sclerosis, multiple sclerosis
InfliximabRemicademabchimericTNF-αYrheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[80][81]mabhumanCD51solid tumors (prostate cancer, melanoma)
InolimomabmabmouseCD25 (α chain of IL-2 receptor)graft versus host disease
Inotuzumab ozogamicin[38]BesponsamabhumanizedCD22YAcute lymphoblastic leukemia (ALL)
Ipilimumab[55]YervoymabhumanCD152Ymelanoma
Iomab-BmouseCD45ablation of bone marrow
Iratumumab[55]mabhumanCD30 (TNFRSF8)Hodgkin's lymphoma
IsatuximabSarclisamabchimericCD38Ymultiple myeloma
Iscalimab[5]mabhumanCD40
Istiratumab[26]mabhumanIGF-1 receptor (CD221)advanced solid tumors
Itolizumab[72]AlzumabmabhumanizedCD6Ypsoriasis
IxekizumabTaltzmabhumanizedIL-17AYautoimmune diseases
KeliximabmabchimericCD4chronic asthma
Labetuzumab[7]CEA-CidemabhumanizedCarcinoembryonic antigen (CEA)colorectal cancer
Lacnotuzumab[27]mabhumanizedCSF1, macrophage colony stimulating factor (MCSF)cancer
Ladiratuzumab vedotin[26]mabhumanizedLIV-1cancer
Lampalizumab[15]FabhumanizedComplement factor D (CFD)geographic atrophy secondary to age-related macular degeneration
Lanadelumab[40]TakhzyromabhumankallikreinYangioedema
Landogrozumab[12]mabhumanizedGDF-8muscle wasting disorders
Laprituximab emtansine[40]mabchimericepidermal growth factor receptor (EGFR)
Larcaviximab[27]mabchimericebolavirus glycoproteinEbola virus
LebrikizumabmabhumanizedIL-13asthma
Lecanemab[82]Leqembimabhumanizedβ-amyloidY[83]Alzheimer's disease
Lemalesomab[64]mabmouseNCA-90 (granulocyte antigen)diagnostic agent
Lendalizumab[40]mabhumanizedC5
Lenvervimab[5]mabhumanizedhepatitis B surfage antigenhepatitis B
Lenzilumab[6]mabhumanCSF2chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia
Lerdelimumab[17]mabhumanTGF-β2reduction of scarring after glaucoma surgery
Leronlimab[5]mabhumanizedCCR5breast cancer, HIV
Lesofavumab[27]mabhumanHemagglutinin (influenza)
Letolizumab[27]scFvhumanizedtumor necrosis factor related activation protein (TRAP)inflammatory diseases
Lexatumumab[1]mabhumanTRAIL-R2cancer
Libivirumab[65]mabhumanhepatitis B surface antigenhepatitis B
Lifastuzumab vedotinmabhumanizedphosphate-sodium co-transportercancer
Ligelizumab[15]mabhumanizedIGHEsevere asthma, chronic spontaneous urticaria
Loncastuximab tesirine[84][71]ZynlontamabchimericCD19Yrelapsed or refractory large B-cell lymphoma
Losatuxizumab vedotin[27]mabchimeric/
humanized
epidermal growth receptor factor (EGRF), ERBB1 HER1cancer
Lilotomab satetraxetan[25]mabmouseCD37cancer
LintuzumabmabhumanizedCD33cancer
Lirilumab[15]mabhumanKIR2Dsolid and hematological cancers
Lodelcizumab[39]mabhumanizedPCSK9hypercholesterolemia
Lokivetmab[25]Cytopoint[85]mabveterinaryCanis lupus familiaris IL31Yclinical signs of atopic dermatitis in dogs[85]
Lorvotuzumab mertansinemabhumanizedCD56cancer
Lucatumumab[13]mabhumanCD40multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol[6]mabhumanizedCD28autoimmune diseases
Lumiliximab[9]mabchimericCD23 (IgE receptor)chronic lymphocytic leukemia
Lumretuzumab[6]mabhumanizedERBB3 (HER3)cancer
Lupartumab[22]mabhuman
Lupartumab amadotin[22]mabhumanLYPD3
Lutikizumab[22]mabhumanizedIL-1α
Maftivimabmabhumanpart of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Mapatumumab[30]mabhumanTRAIL-R1cancer
MargetuximabMargenza[86]mabhumanizedHER2Ybreast cancer
Marstacimabmabhumantissue factor pathway inhibitor (TFPI)bleeding with hemophilia
MaslimomabmouseT-cell receptor
Mavrilimumab[37]mabhumanGMCSF receptor α-chainrheumatoid arthritis
Matuzumab[24]mabhumanizedEpidermal growth factor receptor (EGFR)colorectal, lung and stomach cancer
Mepolizumab[46]BosatriamabhumanizedIL-5Yasthma and white blood cell diseases
Metelimumab[24]mabhumanTGF-β1systemic scleroderma
Milatuzumab[13]mabhumanizedCD74multiple myeloma and other hematological malignancies
MinretumomabmabmouseTAG-72tumor detection (and therapy?)
Mirikizumab[84]OmvohmabhumanizedIL-23Yulcerative colitis
Mirvetuximab soravtansine[12]Elaheremabchimericfolate receptor alphaY[87]ovarian cancer
MitumomabmabmouseGD3 gangliosidesmall cell lung carcinoma
ModotuximabmabchimericEGFR extracellular domain IIIcancer
Mogamulizumab[16]PoteligeomabhumanizedCCR4Yadult T-cell leukemia/lymphoma
Monalizumab[12]mabhumanizedNKG2Arheumatoid arthritis, gynecologic malignancies, and other cancers
Morolimumab[88]mabhumanRhesus factor
Mosunetuzumab[84]LunsumioBiTEhumanizedCD3E, MS4A1, CD20Y[89]follicular lymphoma
Motavizumab[1]Numaxmabhumanizedrespiratory syncytial virusrespiratory syncytial virus (prevention)
Moxetumomab pasudotoxLumoxitimabmouseCD22Yhairy cell leukemia
Muromonab-CD3[90][91]Orthoclone OKT3mabmouseCD3prevention of organ transplant rejections
Nacolomab tafenatoxFabmouseC242 antigencolorectal cancer
Namilumab[16]mabhumanCSF2
Naptumomab estafenatox[92]Fabmouse5T4non-small cell lung carcinoma, renal cell carcinoma
Naratuximab emtansine[40]mabchimericCD37
NarnatumabmabhumanMST1R (aka RON)cancer
Natalizumab[88]Tysabrimabhumanizedintegrin α4Ymultiple sclerosis, Crohn's disease
Navicixizumab[40]mabchimeric/
humanized
DLL4 and VEGFAcancer
Navivumab[12]mabhumanHemagglutinin (influenza)
NaxitamabDanyelzahumanizedc-MetYhigh-risk neuroblastoma and refractory osteomedullary disease
Nebacumabmabhumanendotoxinsepsis
Necitumumab[93]PortrazzamabhumanEpidermal growth factor receptor (EGFR)Ynon-small cell lung carcinoma
Nemolizumab[25]mabhumanizedIL-31 receptor Aeczema[94]
NEOD001humanizedamyloidprimary systemic amyloidosis
NerelimomabmabmouseTNF-α
Nesvacumabmabhumanangiopoietin 2cancer
Netakimab[5]EfleiramabchimericIL-17Aplaque psoriasis
Nimotuzumab[55][95]BioMab-EGFR, Theracim, Theralocmabhumanizedepidermal growth factor receptor (EGFR)Ysquamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
NirsevimabmabhumanRSV fusion glycoproteinrespiratory syncytial virus
Nivolumab[6]OpdivomabhumanPD-1Ycancer
Nofetumomab merpentanVerlumaFabmousecancer (diagnosis)
ObiltoxaximabAnthimmabchimericBacillus anthracis anthraxYBacillus anthracis spores
ObinutuzumabGazyvamabhumanizedCD20Ychronic lymphatic leukemia
OcaratuzumabmabhumanizedCD20cancer
Ocrelizumab[96]OcrevusmabhumanizedCD20Ymultiple sclerosis
Odesivimabmabhumanpart of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
OdulimomabmabmouseLFA-1 (CD11a)prevention of organ transplant rejections, immunological diseases
Ofatumumab[30]Arzerra, Kesimpta[97]mabhumanCD20Ychronic lymphocytic leukemia, multiple sclerosis[97]
OlaratumabLartruvomabhumanPDGFRAYcancer
Oleclumab[27]mabhuman5'-nucleotidasepancreatic and colorectal cancer
Olendalizumab[27]mabhumanizedcomplement C5asystemic lupus erythematosus, lupus nephritis, acute graft-versus-hose disease
Olokizumab[72]mabhumanizedIL-6rheumatoid arthritis
Omalizumab[64]XolairmabhumanizedIgE Fc regionYallergic asthma, chronic spontaneous urticaria
Omburtamab[57]mabmouseCD276cancer
OMS721humanMASP-2atypical hemolytic uremic syndrome
OnartuzumabFabhumanizedhuman scatter factor receptor kinasecancer
Ontuxizumabmabchimeric/
humanized
TEM1cancer
Onvatilimab[5]mabhumanVISTA (protein) (VSIR)
OpicinumabmabhumanLINGO-1multiple sclerosis
Oportuzumab monatox[93]ViciniumscFvhumanizedEpCAMbladder cancer
Oregovomab[17]OvaRexmabmouseCA-125ovarian cancer
Orticumab[15]mabhumanoxLDL
Otelixizumab[13]mabchimeric/
humanized
CD3diabetes mellitus type 1
OtilimabmabhumanGMCSFosteoarthritis, rheumatoid arthritis
OtlertuzumabmabhumanizedCD37cancer
Oxelumab[41]mabhumanOX-40asthma
OzanezumabmabhumanizedNOGO-AALS and multiple sclerosis
Ozoralizumab[41]mabhumanizedTNF-αinflammation
Pagibaximab[30]mabchimericlipoteichoic acidsepsis (Staphylococcus)
PalivizumabSynagis, AbbosynagismabhumanizedF protein of respiratory syncytial virusYrespiratory syncytial virus (prevention)
Pamrevlumab[12]mabhumanconnective tissue growth factor (CTGF)idiopathic pulmonary fibrosis (IPF), pancreatic cancer
Panitumumab[65]Vectibixmabhumanepidermal growth factor receptor (EGFR)Ycolorectal cancer
Pankomabmabhumanizedtumor specific glycosylation of MUC1ovarian cancer
Panobacumab[93]mabhumanPseudomonas aeruginosaPseudomonas aeruginosa infection
Parsatuzumab[15]mabhumanizedEGFL7cancer
Pascolizumab[21]mabhumanizedIL-4asthma
Pasotuxizumab[6]mabchimeric/
humanized
folate hydrolasecancer
Pateclizumab[41]mabhumanizedlymphotoxin alpha (LTA)TNF
Patritumab[43]mabhumanERBB3 (HER3)cancer
PDR001humanizedPD-1melanoma
Pembrolizumab[52]KeytrudamabhumanizedPD-1Y[98]melanoma and other cancers
PemtumomabTheragynmouseMUC1cancer
Perakizumab[15]mabhumanizedIL-17Aarthritis
PertuzumabPerjetamabhumanizedHER2/neuYcancer
Pexelizumab[17]scFvhumanizedC5reduction of side effects of cardiac surgery
Pidilizumab[39]mabhumanizedPD-1cancer and infectious diseases
Pinatuzumab vedotin[39]mabhumanizedCD22cancer
Pintumomabmabmouseadenocarcinoma antigenadenocarcinoma (imaging)
Placulumab[15]mabhumanTNFpain and inflammatory diseases
Pozelimab[34]VeopozmabhumanC5YCHAPLE disease
Prezalumab[40]mabhumanTNF
Plozalizumab[12]mabhumanizedCCR2diabetic nephropathy and arteriovenous graft patency
Pogalizumab[40]mabhumanizedtumor necrosis factor receptor (TNFR) superfamily member 4
Polatuzumab vedotin[50][4]PolivymabhumanizedCD79BYdiffuse large B-cell lymphoma
Ponezumabmabhumanizedβ-amyloidAlzheimer's disease
Porgaviximab[27]mabchimericZaire ebolavirus glycoproteinEbola virus disease
Prasinezumab[26]mabhumanizedAlpha-synucleinParkinson's disease
Prezalizumab[40]mabhumanizedinducible T-cell co-stimulatory ligand (ICOSL)
PriliximabmabchimericCD4Crohn's disease, multiple sclerosis
Pritoxaximab[39]mabchimericE. coli shiga toxin type-1
Pritumumabmabhumanvimentinbrain cancer
PRO 140humanizedCCR5HIV infection
Quilizumab[43]mabhumanizedIGHEasthma
Racotumomab[93]VaxiramabmouseNGNA gangliosideYnon-small cell lung cancer
Radretumab[16]mabhumanfibronectin extra domain-Bcancer
Rafivirumab[48]mabhumanrabies virus glycoproteinrabies (prophylaxis)
RalpancizumabmabhumanizedPCSK9dyslipidemia
RamucirumabCyramzamabhumanVEGFR2Ysolid tumors
RanevetmabmabveterinaryNGFosteoarthritis in dogs
Ranibizumab[9]LucentisFabhumanizedVEGF-AYmacular degeneration (wet form)
Raxibacumab[38]mabhumananthrax toxin, protective antigenYanthrax (prophylaxis and treatment)
Ravagalimab[5]mabhumanizedCD40Crohn's disease
Ravulizumab[26]UltomirismabhumanizedC5Yparoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Refanezumabmabhumanizedmyelin-associated glycoproteinrecovery of motor function after stroke
Regavirumabmabhumancytomegalovirus glycoprotein Bcytomegalovirus infection
Regdanvimab[28]Regkirona[99]mabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Y[99]COVID-19
RelatlimabmabhumanLAG3melanoma
Remtolumab[22]mabhumanIL-17A, TNF
Reslizumab[7]CinqairmabhumanizedIL-5Yinflammations of the airways, skin and gastrointestinal tract
Retifanlimab[60]Zynyz[100]mabhumanizedPD-1YMerkel cell carcinoma
Rilotumumabmabhumanhepatocyte growth factor (HGF)solid tumors
RinucumabmabhumanPDGFRBneovascular age-related macular degeneration
Risankizumab[12]SkyrizimabhumanizedIL-23AYCrohn's disease, psoriasis, psoriatic arthritis, and asthma
RituximabMabThera, RituxanmabchimericCD20Y[101]lymphomas, leukemias, some autoimmune disorders
Rivabazumab pegol[12]mabhumanizedPseudomonas aeruginosa type III secretion system
RobatumumabmabhumanIGF-1 receptor (CD221)cancer
RmabRabiShieldhumanrabies virus G glycoproteinYpost-exposure prophylaxis of rabies
Roledumab[72]mabhumanRHD (gene) (RHD)Rh disease
Romilkimab[5]mabchimeric/
humanized
IL-13
RomosozumabEvenitymabhumanizedsclerostinYosteoporosis
Rontalizumab[53]mabhumanizedIFN-αsystemic lupus erythematosus
Rosmantuzumab[22]mabhumanizedroot plate-specific spondin 3cancer
Rovalpituzumab tesirine[12]mabhumanizedDLL3small cell lung cancer
Rovelizumab[46]LeukArrestmabhumanizedCD11, CD18Yhaemorrhagic shock etc.
Rozanolixizumab[22]Rystiggomabchimeric/
humanized
FCGRTY[102] myasthenia gravis
Ruplizumab[14]AntovamabhumanizedCD154 (CD40L)Yrheumatic diseases
SA237humanizedIL-6 receptorneuromyelitis optica and neuromyelitis optica spectrum disorders
Sacituzumab govitecan[22]TrodelvymabhumanizedTROP-2Y[103]triple-negative breast cancer
Samalizumab[41]mabhumanizedCD200cancer
Samrotamab vedotin[5]mabchimeric/
humanized
LRRC15cancer
Sarilumab[43]KevzaramabhumanIL-6Yrheumatoid arthritis, ankylosing spondylitis
Satralizumab[73]EnspryngmabhumanizedIL-6 receptorYneuromyelitis optica
Satumomab pendetidemabmouseTAG-72cancer (diagnosis)
SecukinumabCosentyxmabhumanIL-17AYuveitis, rheumatoid arthritis psoriasis
Selicrelumab[27]mabhumanCD40
Seribantumab[39]mabhumanERBB3 (HER3)cancer
Setoxaximab[39]mabchimericE. coli shiga toxin type-2
Setrusumab[26]mabhumansclerostin (SOST)
Sevirumabhumancytomegaloviruscytomegalovirus infection
SibrotuzumabmabhumanizedFAP (gene) (FAP)cancer
SGN-CD19AmabhumanizedCD19acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SHP647humanmucosal addressin cell adhesion moleculeCrohn's disease
Sifalimumab[16]mabhumanIFN-αsystemic lupus erythematosus (SLE), dermatomyositis, polymyositis
SiltuximabSylvantmabchimericIL-6Ycancer
Simtuzumab[15]mabhumanizedLOXL2fibrosis
Siplizumab[21]mabhumanizedCD2psoriasis, graft-versus-host disease (prevention)
Sirtratumab vedotin[26]mabhumanSLITRK6cancer
SirukumabmabhumanIL-6rheumatoid arthritis
Sofituzumab vedotinmabhumanizedCA-125ovarian cancer
Solanezumab[93]mabhumanizedβ-amyloidAlzheimer's disease
Solitomab[43]BiTEmouseEpCAMgastrointestinal, lung, and other cancers
Sonepcizumab[104]humanizedsphingosine-1-phosphatechoroidal and retinal neovascularization
Sontuzumab[95]mabhumanizedepisialin
Sotrovimab[28]Xevudymabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Y[105][106]COVID-19
Spartalizumab[26]mabhumanizedPD-1melanoma
Spesolimab[107]SpevigomabhumanizedInterleukin 36 receptor (IL1RL2/IL1RAP)Ygeneralized pustular psoriasis (GPP)
Stamulumab[96]mabhumanmyostatinmuscular dystrophy
SulesomabLeukoScanFab'mouseNCA-90 (granulocyte antigen)osteomyelitis (imaging)
Suptavumab[22]mabhumanRSVFRmedically attended lower respiratory disease
Sutimlimab[66]Enjaymomabchimeric/
humanized
complement component 1s (C1s)Ycold agglutinin disease
Suvizumab[37]mabhumanizedHIV-1viral infections
Suvratoxumab[27]mabhumanStaphylococcus aureus alpha toxinnosocomial pneumonia
Tabalumab[41]mabhumanB-cell activating factor (BAFF)B-cell cancers
Tacatuzumab tetraxetanAFP-Cidemabhumanizedalpha-fetoproteincancer
Tadocizumab[95]Fabhumanizedintegrin αIIbβ3percutaneous coronary intervention
Tafasitamab[46]Monjuvimabhumanized
(from mouse)
CD19Yrelapsed or refractory diffuse large B-cell lymphoma
Talacotuzumab[26]mabhumanizedCD123leukemia etc.
Talizumab[36]mabhumanizedIgEallergic reaction
TalquetamabTalveyBsAbhumanizedGPRC5D, CD3Yrelapsed or refractory multiple myeloma
Tamtuvetmab[40]TactressmabveterinaryCD52
Tanezumab[48]mabhumanizednerve growth factor (NGF)pain
Taplitumomab paptox[64]mabmouseCD19cancer
TarextumabmabhumanNotch receptorcancer
Tavolimabmabchimeric/
humanized
CD134cancer
TeclistamabTecvayli[34]BsAbhumanB-cell maturation antigen (BCMA), CD3Y[108][109]relapsed or refractory multiple myeloma
Tefibazumab[38]Aurexismabhumanizedclumping factor AStaphylococcus aureus infection
Telimomab aritoxFabmouse
Telisotuzumab[22]mabhumanizedHGFRcancer
Telisotuzumab vedotin[22]mabhumanizedHGFRcancer
Tenatumomab[13]mabmousetenascin Ccancer
Teneliximab[21]mabchimericCD40autoimmune diseases and prevention of organ transplant rejection
Teplizumab[42]TzieldmabhumanizedCD3Ydiabetes mellitus type 1
Tepoditamab[5]mabhumandendritic cell-associated lectin 2cancer
TeprotumumabTepezzamabhumanIGF-1 receptor (CD221)Ythyroid eye disease
Tesidolumab[25]mabhumanC5
TetulomabmabhumanizedCD37cancer[110]
Tezepelumab[12]Tezspiremabhumanthymic stromal lymphopoietin (TSLP)Y[111]asthma
TGN1412humanizedCD28chronic lymphocytic leukemia, rheumatoid arthritis
Tibulizumab[26]mabhumanizedB-cell activating factor (BAFF)autoimmune disorders
TildrakizumabIlumyamabhumanizedIL-23Yimmunologically mediated inflammatory disorders
Tigatuzumab[13]mabhumanizedTRAIL-R2cancer
Timigutuzumab[27]mabhumanizedHER2cancer
Timolumab[40]mabhumanAOC3
tiragolumab[26]mabhuman
Tiragotumab[26]mabhumanTIGITcancer
Tislelizumab[26]mabhumanizedPCDC1, CD279non-small cell lung cancer
Tisotumab vedotin[12]Tivdakmabhumancoagulation factor IIIYrelapsed or refractory cervical cancer[112][113]
Tixagevimab[28]mabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2Emergency Use Authorization (EUA) when used with cilgavimab[47]COVID-19
TNX-650humanizedIL-13Hodgkin's lymphoma
Tocilizumab[9]Actemra, RoActemramabhumanizedIL-6 receptorY[114]rheumatoid arthritis
Tomuzotuximab[27]mabhumanizedEpidermal growth factor receptor (EGFR), HER1cancer
Toralizumab[21]mabhumanizedCD154 (CD40L)rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab[4]mabhumanStaphylococcus aureus
TositumomabBexxarmouseCD20Yfollicular lymphoma
TovetumabmabhumanPDGFRAcancer
Tralokinumab[115]Adtralza, Adbry[116]mabhumanIL-13Y[116]atopic dermatitis
TrastuzumabHerceptinmabhumanizedHER2/neuYbreast cancer
Trastuzumab duocarmazine[22]KadcylamabhumanizedHER2/neuYbreast cancer
Trastuzumab emtansineKadcylamabhumanizedHER2/neuYbreast cancer
TRBS07[117]Ektomab3functGD2 gangliosidemelanoma
Tregalizumab[16]mabhumanizedCD4
Tremelimumab[118]ImjudomabhumanCTLA-4Y[119]hepatocellular carcinoma
Trevogrumabmabhumangrowth differentiation factor 8muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin[55][95]mabhumanizedEpCAMcancer
Tuvirumabhumanhepatitis B viruschronic hepatitis B
Ublituximab[120]BriumvimabchimericCD20Ymultiple sclerosis, chronic lymphocytic leukemia
Ulocuplumab[52]mabhumanCXCR4 (CD184)hematologic malignancies
Urelumab[16]mabhuman4-1BB (CD137)cancer etc.
Urtoxazumab[9]mabhumanizedEscherichia colidiarrhoea caused by E. coli
Ustekinumab[48]StelaramabhumanIL-12, IL-23Ymultiple sclerosis, psoriasis, psoriatic arthritis
Utomilumab[22]mabhuman4-1BB (CD137)diffuse large B-cell lymphoma
Vadastuximab talirine[12]mabchimericCD33Acute myeloid leukemia
Vanalimab[5]mabhumanizedCD40
Vandortuzumab vedotin[25]mabhumanizedSTEAP1cancer
VantictumabmabhumanFrizzled receptorcancer
Vanucizumab[6]mabhumanizedangiopoietin 2cancer
Vapaliximab[21]mabchimericAOC3 (VAP-1)
Varisacumab[27]mabhumanVEGF-Aangiogenesis
Varlilumab[6]mabhumanCD27solid tumors and hematologic malignancies
Vatelizumab[41]mabhumanizedITGA2 (CD49b)
Vedolizumab[93]Entyviomabhumanizedintegrin α4 β7Y[121]Crohn's disease, ulcerative colitis
Veltuzumab[13]mabhumanizedCD20non-Hodgkin's lymphoma
VepalimomabmabmouseAOC3 (VAP-1)inflammation
Vesencumab[16]mabhumanNRP1solid malignancies
Vilobelimab[82]GohibicmabchimericC5a receptor (C5a)Emergency Use Authorization (EUA)[122]COVID-19
Visilizumab[64]NuvionmabhumanizedCD3Crohn's disease, ulcerative colitis
Vobarilizumab[40]scFvhumanizedIL-6 receptorinflammatory autoimmune diseases
Volociximab[30]mabchimericintegrin α5β1solid tumors
Vonlerolizumab[27]mabhumanizedCD134cancer
Vopratelimab[5]mabhumanizedCD278, aka ICOS
Vorsetuzumab mafodotinmabhumanizedCD70cancer
VotumumabHumaSPECTmabhumantumor antigen CTAA16.88colorectal tumors
Vunakizumab[22]mabhumanizedIL-17A
Xentuzumab[40]mabhumanizedIGF-1, IGF-2?
XMAB-5574humanizedCD19diffuse large B-cell lymphoma
Zalutumumab[30]mabhumanEpidermal growth factor receptor (EGFR)squamous cell carcinoma of the head and neck
Zanolimumab[38]mabhumanCD4rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab[15]mabchimericHER1cancer
Zenocutuzumab[26]mabhumanizedERBB3 (HER3)cancer
Ziralimumab[64]mabhumanCD147 (basigin)
Zolbetuximab[26]mabchimericClaudin 18 Isoform 2gastric cancer, gastrointestinal adenocarcinoma and pancreatic cancer
Zolimomab aritoxmabmouseCD5systemic lupus erythematosus, graft-versus-host disease

References

  1. 1 2 3 4 5 World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 57". WHO Drug Information. 21 (1). hdl:10665/74004.
  2. 1 2 3 World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 80" (PDF). WHO Drug Information. 12 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  3. "ReoPro Abciximab". DailyMed. 4 May 2020. Archived from the original on 6 September 2022. Retrieved 28 June 2022.
  4. 1 2 3 4 5 6 7 8 9 10 World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1). hdl:10665/331151.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 118" (PDF). WHO Drug Information. 31 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 111" (PDF). WHO Drug Information. 28 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.
  7. 1 2 3 4 World Health Organization (2001). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 85" (PDF). WHO Drug Information. 15 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  8. "Humira- adalimumab kit Humira- adalimumab injection, solution". DailyMed. Archived from the original on 21 June 2020. Retrieved 18 February 2020.
  9. 1 2 3 4 5 World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 90" (PDF). WHO Drug Information. 18 (1). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
  10. 1 2 World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.
  11. "Aduhelm- aducanumab injection, solution". DailyMed. Archived from the original on 14 June 2021. Retrieved 14 June 2021.
  12. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.
  13. 1 2 3 4 5 6 7 8 9 World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 98" (PDF). WHO Drug Information. 21 (4). Archived (PDF) from the original on 3 March 2016. Retrieved 5 October 2020.
  14. 1 2 3 World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 83" (PDF). WHO Drug Information. 14 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
  15. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 107" (PDF). WHO Drug Information. 26 (2). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
  16. 1 2 3 4 5 6 7 8 9 10 11 World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104" (PDF). WHO Drug Information. 24 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  17. 1 2 3 4 5 World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 86" (PDF). WHO Drug Information. 16 (1). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  18. 1 2 3 World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 115" (PDF). WHO Drug Information. 30 (2). Archived (PDF) from the original on 5 February 2018. Retrieved 5 October 2020.
  19. "Saphnelo- anifrolumab injection, solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.
  20. "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on 12 June 2008. Retrieved 19 November 2008.
  21. 1 2 3 4 5 6 7 8 9 World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 87" (PDF). WHO Drug Information. 16 (2). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
  22. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl:10665/330984.
  23. World Health Organization (1995). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 74" (PDF). WHO Drug Information. 9 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 24 January 2020.
  24. 1 2 3 4 World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 88" (PDF). WHO Drug Information. 17 (1). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  25. 1 2 3 4 5 6 7 8 9 10 11 World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 112" (PDF). WHO Drug Information. 28 (4). Archived (PDF) from the original on 28 August 2021. Retrieved 5 October 2020.
  26. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 117" (PDF). WHO Drug Information. 31 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.
  27. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 116" (PDF). WHO Drug Information. 30 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
  28. 1 2 3 4 5 6 7 8 World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.
  29. 1 2 "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab and Etesevimab" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 18 March 2021. Retrieved 18 March 2021.
  30. 1 2 3 4 5 6 7 8 World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 93" (PDF). WHO Drug Information. 19 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  31. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 World Health Organization (2019). International Nonproprietary Names (INN) for biological and biotechnological substances (PDF). World Health Organization (WHO). WHO/EMP/RHT/TSN/2019.1. Archived (PDF) from the original on 19 January 2022. Retrieved 22 January 2020.
  32. World Health Organization (2021). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 126 – COVID-19 (special edition)". WHO Drug Information. 35 (4): 1130–1. Archived from the original on 13 February 2022. Retrieved 13 February 2022.
  33. "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bebtelovimab" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 11 February 2022. Retrieved 12 February 2022.
  34. 1 2 3 World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.
  35. 1 2 3 "Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 via Business Wire.
  36. 1 2 World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 89" (PDF). WHO Drug Information. 17 (3).
  37. 1 2 3 4 World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 102" (PDF). WHO Drug Information. 23 (4). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  38. 1 2 3 4 5 World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 92" (PDF). WHO Drug Information. 18 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  39. 1 2 3 4 5 6 7 8 9 World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 108" (PDF). WHO Drug Information. 26 (4). Archived (PDF) from the original on 4 March 2016. Retrieved 5 October 2020.
  40. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 114" (PDF). WHO Drug Information. 29 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
  41. 1 2 3 4 5 6 7 8 9 10 11 World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 105" (PDF). WHO Drug Information. 25 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  42. 1 2 3 4 5 World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 97" (PDF). WHO Drug Information. 21 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  43. 1 2 3 4 5 6 World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 106" (PDF). WHO Drug Information. 25 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
  44. 1 2 "Ronapreve EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 13 November 2021. Retrieved 12 November 2021.
  45. 1 2 "Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19". Roche (Press release). 20 July 2021. Archived from the original on 24 July 2021. Retrieved 29 August 2021.
  46. 1 2 3 4 World Health Organization (1999). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 81" (PDF). WHO Drug Information. 13 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  47. 1 2 "Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals". U.S. Food and Drug Administration (FDA) (Press release). 8 December 2021. Archived from the original on 28 April 2022. Retrieved 9 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  48. 1 2 3 4 5 6 World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 99" (PDF). WHO Drug Information. 22 (2). Archived (PDF) from the original on 25 October 2021. Retrieved 5 October 2020.
  49. "BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009. Archived from the original on 13 November 2009. Retrieved 11 November 2009.
  50. 1 2 World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
  51. World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 78" (PDF). WHO Drug Information. 11 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
  52. 1 2 3 World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 110" (PDF). WHO Drug Information. 27 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
  53. 1 2 3 4 World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 101" (PDF). WHO Drug Information. 23 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  54. "Darzalex- daratumumab injection, solution, concentrate Darzalex IV- daratumumab injection, solution, concentrate". DailyMed. Archived from the original on 19 December 2021. Retrieved 18 December 2021.
  55. 1 2 3 4 5 World Health Organization (2005). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 94" (PDF). WHO Drug Information. 19 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  56. World Health Organization (1991). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 66" (PDF). WHO Drug Information. 5 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
  57. 1 2 3 World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 119" (PDF). WHO Drug Information. 32 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 5 October 2020.
  58. "Padcev ejfv- enfortumab vedotin injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 11 December 2021. Retrieved 18 December 2021.
  59. World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 77" (PDF). WHO Drug Information. 11 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  60. 1 2 3 World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
  61. World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.
  62. World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 51" (PDF). WHO Drug Information. 18 (1). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  63. "Vyepti- eptinezumab-jjmr injection". DailyMed. Archived from the original on 28 September 2021. Retrieved 27 September 2021.
  64. 1 2 3 4 5 6 7 World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 84" (PDF). WHO Drug Information. 14 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  65. 1 2 3 4 World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 91" (PDF). WHO Drug Information. 18 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  66. 1 2 World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.
  67. Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.
  68. Boehrer, S; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160. S2CID 29327089.
  69. Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
  70. Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
  71. 1 2 World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 113" (PDF). WHO Drug Information. 29 (2). Archived (PDF) from the original on 4 November 2021. Retrieved 5 October 2020.
  72. 1 2 3 4 World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 103" (PDF). WHO Drug Information. Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  73. 1 2 World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.
  74. 1 2 3 "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  75. "Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®" (Press release). Archived from the original on 7 July 2017. Retrieved 2 May 2011.
  76. NCI Drug Dictionary: Glemtumumab vedotin Archived 5 April 2015 at the Wayback Machine
  77. 1 2 3 "FDA approves Roche's Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma" (Press release). F. Hoffmann-La Roche Ltd. 16 June 2023. Retrieved 16 June 2023 via GlobeNewswire.
  78. "Results from Cure Brain Cancer Foundation-funded trial show promise". www.curebraincancer.org.au. Archived from the original on 19 March 2020. Retrieved 14 June 2019.
  79. "Uplizna- inebilizumab injection". DailyMed. 8 July 2019. Archived from the original on 13 June 2020. Retrieved 13 June 2020.
  80. Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
  81. Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
  82. 1 2 World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl:10665/340680.
  83. "FDA Grants Accelerated Approval for Alzheimer's Disease Treatment". U.S. Food and Drug Administration (FDA) (Press release). 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023.
  84. 1 2 3 World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.
  85. 1 2 Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. Archived from the original on 7 July 2018. Retrieved 6 July 2018.
  86. "Margenza: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 23 March 2021. Retrieved 17 December 2020.
  87. "FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer". U.S. Food and Drug Administration (FDA). 14 November 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.
  88. 1 2 World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 79" (PDF). WHO Drug Information. 12 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  89. "FDA grants accelerated approval to mosunetuzumab-axgb". U.S. Food and Drug Administration. 22 December 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023.
  90. Wilde, Michelle I.; Goa, Karen L. (1 May 1996). "Muromonab CD3". Drugs. 51 (5): 865–894. doi:10.2165/00003495-199651050-00010. ISSN 1179-1950. PMID 8861551. S2CID 13220985.
  91. Hooks, M. A.; Wade, C. S.; Millikan, W. J. (1991). "Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation". Pharmacotherapy. 11 (1): 26–37. ISSN 0277-0008. PMID 1902291. Archived from the original on 10 September 2021. Retrieved 10 September 2021.
  92. World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 96" (PDF). WHO Drug Information. 20 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  93. 1 2 3 4 5 6 World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 100 (prepublication copy)" (PDF). WHO Drug Information. Archived (PDF) from the original on 29 August 2021. Retrieved 5 October 2020.
  94. Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grazyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Yoshida, Hiroki; Stewart, Jonathan; Kabashima, Kenji; XCIMA Study Group (2017). "Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis". New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.
  95. 1 2 3 4 World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 56" (PDF). WHO Drug Information. 20 (3). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  96. 1 2 World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 95" (PDF). WHO Drug Information. 20 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  97. 1 2 "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis" (Press release). Novartis. 20 August 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
  98. "Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". DailyMed. 17 September 2019. Archived from the original on 17 June 2020. Retrieved 10 January 2020.
  99. 1 2 "Regkirona EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021.
  100. "ZYNYZ™ (retifanlimab-dlwr) injection, for intravenous use" (PDF). Archived (PDF) from the original on 23 March 2023. Retrieved 23 March 2023.
  101. "Rituxan- rituximab injection, solution". DailyMed. 6 November 2019. Archived from the original on 4 August 2020. Retrieved 2 February 2020.
  102. "UCB announces U.S. FDA approval of Rystiggo (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis" (Press release). UCB. 27 June 2023. Retrieved 28 June 2023 via PR Newswire.
  103. "Trodelvy- sacituzumab govitecan powder, for solution". DailyMed. Archived from the original on 20 March 2021. Retrieved 9 April 2021.
  104. Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.
  105. "AusPAR: Sotrovimab". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 1 November 2021. Retrieved 4 September 2021.
  106. "Xevudy EPAR". European Medicines Agency (EMA). 15 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.
  107. World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
  108. "Janssen Marks First Approval Worldwide for Tecvayli (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma". Janssen Pharmaceutical Companies (Press release). 24 August 2022. Archived from the original on 26 October 2022. Retrieved 26 October 2022.
  109. "U.S. FDA Approves Tecvayli (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma". Janssen Pharmaceutical Companies. 25 October 2022. Retrieved 26 October 2022.
  110. Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer Research. 33 (1): 85–95. PMID 23267131.
  111. "Tezspire- tezepelumab-ekko injection, solution". DailyMed. 17 December 2021. Archived from the original on 25 December 2021. Retrieved 28 June 2022.
  112. Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Beyond The Printed Page. Archived from the original on 23 February 2018. Retrieved 22 February 2018.
  113. "Enforcement Reports" (PDF). Archived (PDF) from the original on 21 September 2021. Retrieved 21 September 2021.
  114. "RoActemra EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 18 December 2021. Retrieved 18 December 2021.
  115. World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 64". WHO Drug Information. 24 (3). hdl:10665/74577.
  116. 1 2 "LEO Pharma announces FDA approval of Adbry tralokinumab". LEO Pharma (Press release). Archived from the original on 28 December 2021. Retrieved 28 December 2021.
  117. Ruf, P; Jäger, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099. S2CID 25197165.
  118. World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 59". WHO Drug Information. 22 (1). hdl:10665/74120.
  119. "Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer". AstraZeneca (Press release). 26 October 2022. Archived from the original on 24 October 2022. Retrieved 26 October 2022.
  120. World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). hdl:10665/74683.
  121. "Entyvio- vedolizumab injection, powder, lyophilized, for solution". DailyMed. 3 April 2020. Archived from the original on 21 October 2020. Retrieved 12 October 2020.
  122. "FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19". U.S. Food and Drug Administration (FDA). 4 April 2023. Retrieved 4 April 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.